Aadi Bioscience amends bylaws to revise director nomination procedures and conform to Delaware law

Whitehawk Therapeutics, Inc.

Board amended and restated bylaws effective Dec 6, 2022, adding requirement for stockholders to deliver Rule 14a-19 compliance evidence 5 business days before meeting.
Revised procedures for stockholder director nominations and proposals to align with recent DGCL amendments.
Updated provisions regarding directors, Board committees, and officers; made ministerial and clarifications changes.

item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Whitehawk Therapeutics, Inc.: 董事会修订并重述了公司章程，以更新董事提名程序、股东会议程序并符合DGCL (effective 2022-12-06).

Change: bylaw amendment
Effective: 2022-12-06

Exact text from the filing

On December 6, 2022, the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”), acting upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s amended and restated bylaws, effective immediately.

View on SEC.gov

51 governance changes filed in the last 30 days. Browse all governance changes →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-300219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.